Bartlett HIV/AIDS Review: September 15, 2004 Dr. Bartlett reviews the latest data on TDF vs d4T, FTC vs d4T, EFV vs ATZ, hyperlactatemia after NRTI switch, HAART and sexual risk-taking, cancer risk ...

For decades, scientists have recognized that human immunodeficiency virus (HIV) is a formidable viral pathogen. After years ...

The conference emphasized advancements in HIV pathogenesis, persistence, and gene therapy, alongside policy and drug use intersections. Lenacapavir was found safe in adolescents, offering new insights ...

In a first, the study published in the journal Emerging Microbes and Infections demonstrated the team’s patented therapeutic candidate, an HIV-virus-like-particle (HLP), is 100 times more effective ...

The human immunodeficiency virus (HIV) has stubbornly stated that it is here to stay, causing the devastating HIV/AIDS epidemic. Fortunately, human stubbornness and resilience are not in short supply ...

The autophagy process, a critical regulator of T-cell function, has been shown to control acute HIV-1 infection and play a crucial role also in HIV-1 disease pathogenesis. Moreover, previous studies ...

We might be a step closer to curing HIV, as researchers have developed a way to knock out a version of the virus lurking in the body. Using something called an HIV-like particle (HLP)—which are dead ...

At Western University, a bold idea is taking shape: what if lifesaving medical breakthroughs were designed from the very beginning to reach everyone ...

Thumbi Ndung’u consults for Gilead Sciences, Inc. He has received HIV cure-related research grants from Gilead Sciences, Inc, the US NIH, Bill and Melinda Gates Foundation, Wellcome Trust and SFA ...

The New York Course 2007: HIV Pathogenesis -- Expert Interview HIV Management 2007: Dr. Douek speaks with Medscape about the crucial role of profound, early, and persistent depletion of CD4 cells in ...